Now showing items 11-20 of 529
Ponatinib in patients with refractory acute myeloid leukaemia: findings from a phase 1 study
(Wiley Periodicals, Inc., 2013-08)
Factors predictive of failure to complete planned intraoperative breast radiation using the intrabeam® system
(Wiley Periodicals, Inc., 2016-12)
Ixabepilone, mitoxantrone, and prednisone for metastatic castration-resistant prostate cancer after docetaxel-based therapy
(Wiley Subscription Services, Inc., A Wiley Company, 2011-06-01)
BACKGROUND: Mitoxantrone plus prednisone and ixabepilone each have modest activity as monotherapy for second-line chemotherapy in patients with docetaxel-refractory castration-resistant prostate cancer. Clinical noncross- ...
A multi‐institutional phase 2 study of neoadjuvant gemcitabine and oxaliplatin with radiation therapy in patients with pancreatic cancer
(Wiley Periodicals, Inc., 2013-08-01)
Prostate cancer in black men: Is it time for personalized screening approaches?
(NCCNWiley Periodicals, Inc., 2017-06-15)
Mocetinostat for patients with previously treated, locally advanced/metastatic urothelial carcinoma and inactivating alterations of acetyltransferase genes
(Wiley Periodicals, Inc., 2019-02-15)
BackgroundThe authors evaluated mocetinostat (a class I/IV histone deacetylase inhibitor) in patients with urothelial carcinoma harboring inactivating mutations or deletions in CREB binding protein [CREBBP] and/or E1A ...
Variation in prostate cancer treatment and spending among Medicare shared savings program accountable care organizations
(Wiley Periodicals, Inc., 2018-08)
Site‐specific methylation patterns of the GAL and GALR1/2 genes in head and neck cancer: Potential utility as biomarkers for prognosis
(Wiley Periodicals, Inc.Cambridge University Press, 2017-03)
Racial/ethnic differences in clinical trial enrollment, refusal rates, ineligibility, and reasons for decline among patients at sites in the National Cancer Institute's Community Cancer Centers Program
(National Academy of SciencesWiley Periodicals, Inc., 2014-03-15)